EpiHour Seminar Series
During the 2013-2014 school year, the Department of Epidemiology and Population Health is hosting EpiHour, a seminar series that will meet most Thursdays from 12 to 1 p.m. at the School of Public Health and Information Sciences (485 E. Gray St.) All faculty and staff are invited to attend. If you have questions about EpiHour, please contact Dr. Kira Taylor.
|8/29/2013||Dave Hopkins||KY All Schedule Electronic Reporting (KASPER)||001|
|9/05/2013||James Wittliff||Hormone Receptor Lab and Cancer||001|
|9/12/2013||Brad Rodu||Tobacco Harm Reduction||001|
|9/26/2013||Steve Winters||SHBG and the Metabolic Syndrome||001|
|10/03/2013||Richard Baumgartner||Fifteen Years of the Health, Eating, Activity and Lifestyle Study: Summary of Findings||001|
|10/10/2013||David Hein||Epidemiology of NAT2 polymorphisms||001|
|10/31/2013||Avonne Conner||Cancer Epidemiology||103|
|11/07/2013||Jaclyn Nee||Kentucky Cancer Registry||103|
|1/30/2014||Susan Muldoon||Lead Exposure in the Military: A Cause of Neuropsychological Dysfunction?||103|
|2/13/2014||Lisa Crabtree||KIP Survey - Background and Field Procedures||103|
|3/6/2014||Manuel Casanova||Autism and Neuropsychiatry||103|
Sept. 12, 2013
Brad Rodu, D.D.S.
Tobacco Harm Reduction: Making Smoking History
Brad Rodu has been appointed the first holder of the Endowed Chair in Tobacco Harm Reduction Research at the University of Louisville’s James Graham Brown Cancer Center. Dr. Rodu’s research focuses on the substitution of safer tobacco products by smokers who are unable or unwilling to quit smoking with conventional cessation methods because of their addiction to nicotine. His research in comparative epidemiology established the scientific foundation for harm reduction and he continues to study clinical and social interventions aimed at harm reduction.
Sept. 26, 2013
Stephen J. Winters, M.D.
Professor of Medicine, Chief, Division of Endocrinology, Metabolism and Diabetes, University of Louisville
Sex hormone binding globulin (SHBG) and the Metabolic Syndrome
Sex hormone binding globulin (SHBG) transports testosterone and other steroids in the blood, and regulates their metabolic clearance and access to target tissues. SHBG has been found to be a biomarker for metabolic syndrome and type 2 diabetes, but the mechanism(s) for these associations are not known. Our laboratory appears to be the first to examine SHBG expression in human liver.